Form 4: Jazz Pharmaceuticals Director Seamus Mulligan Reports Stock Award

Director Seamus Mulligan reports acquisition of restricted stock units in Jazz Pharmaceuticals.

Summary

• Seamus Mulligan, a director of Jazz Pharmaceuticals plc, reported a transaction on August 2, 2024.
• Mulligan acquired 3,731 ordinary shares through restricted stock units, granted under the company's 2007 Amended and Restated Non-Employee Directors Stock Award Plan.
• The restricted stock units were priced at $0.0 and will vest in full on July 25, 2025, contingent upon continuous service and other conditions.
• Following the transaction, Mulligan beneficially owns 1,176,106 ordinary shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects a standard director compensation practice that aligns interests with shareholders.

Positives

• The grant of restricted stock units aligns the director's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The director's holdings will increase upon vesting of the restricted stock units in July 2025, contingent on continued service.

Industry Context

Stock awards to directors are a common practice in publicly traded companies to incentivize and align their interests with shareholders.

Comparison to Industry Standards

• Director compensation packages, including stock awards, vary significantly across the pharmaceutical industry depending on company size, performance, and governance practices.
• Comparing Jazz Pharmaceuticals' director compensation to peers like Vertex Pharmaceuticals, Biogen, or Gilead Sciences would provide a benchmark for assessing the competitiveness and appropriateness of the award.
• Typical vesting schedules for restricted stock units range from one to four years, with Jazz Pharmaceuticals' vesting period of approximately one year being on the shorter end.

Stakeholder Impact

• The stock award aligns the director's interests with those of shareholders, potentially driving long-term value creation.
• The vesting schedule incentivizes the director to remain engaged and contribute to the company's success.

Key Dates